Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleEditor’s Page

Unacceptable Denials

Johannes Czernin and Martin Allen-Auerbach
Journal of Nuclear Medicine July 2020, 61 (7) 939;
Johannes Czernin
David Geffen School of Medicine at UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Allen-Auerbach
David Geffen School of Medicine at UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Health Net recently denied coverage for Lutathera (177Lu-DOTATATE; Advanced Accelerator Applications) treatment of a patient with a neuroendocrine tumor. The denial letter stated: “According to the Medical Technology Directory, Health Net, Inc. considers Lutathera (lutetium 177Lu dotatate) to be investigational (not proven). This is a drug for the treatment of neuroendocrine tumors (type of cancer). There is not sufficient information in the literature showing its safety and that it works. Your certificate of insurance does not cover investigational services. The request for Lutathera is denied.”

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Johannes Czernin

This denial echoes many others received by patients and their treating physicians (1,2). It shows ignorance about regulatory approvals and published data. It ignores the fact that the Food and Drug Administration approved this drug in January 2018. It also fails to acknowledge Centers for Medicare and Medicaid Services coverage of Lutathera. The denial letter indicates that Health Net simply ignores the extensive published body of evidence indicating the safety and efficacy of this treatment. Should they choose to do so, Health Net experts could Google “Strosberg J,” “NETTER trial,” “theranostics,” or any of dozens of other related terms directly associated with peer-reviewed literature on the extraordinary progress in treating neuroendocrine tumors dating back to the 1990s.

Patients and treating physicians deserve more careful, professional, and well-researched services from health insurance entities than they frequently receive. Hours are currently wasted on paralyzing phone trees and on so-called peer-to-peer discussions—time that could be spent improving patient care. Patients endure additional anxiety at an already difficult time. Lifelong learning should be mandatory not only for practicing physicians but also for those who make crucial decisions about coverage of life-saving treatments.

The reflex denial culture must end. This is a travesty.

Footnotes

  • Published online May 1, 2020.

  • © 2020 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Czernin J,
    2. Allen-Auerbach M,
    3. Calais J
    . Of sheep and wolves: curtailing coverage for essential imaging tests based on flawed use and cost arguments. J Nucl Med. 2019;60:1657–1658.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Czernin J,
    2. Ceci F
    . Aetna and 68Ga-DOTATATE: a sequel to “the injustice of being judged by the errors of others.” J Nucl Med. 2018;59:721–722.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (7)
Journal of Nuclear Medicine
Vol. 61, Issue 7
July 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Unacceptable Denials
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Unacceptable Denials
Johannes Czernin, Martin Allen-Auerbach
Journal of Nuclear Medicine Jul 2020, 61 (7) 939;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Unacceptable Denials
Johannes Czernin, Martin Allen-Auerbach
Journal of Nuclear Medicine Jul 2020, 61 (7) 939;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition
  • Thank You Drs. Ziessman and Knight for Your Many Years of Newsline Coverage
  • More Unacceptable Denials: Now It’s PSMA-Targeted PET/CT Imaging
Show more Editor’s Page

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire